Abstract: Multidrug resistance (MDR) is the major impediment to cancer chemotherapy. The expression of lung resistance-related protein (LRP), a non-ATP-binding cassette (ABC) transporter, is high in tumor cells, resulting in their resistance to a variety of cytotoxic drugs. However, the function of LRP in tumor drug resistance is not yet explicit. Our previous studies had shown that Kinesin KIF4A was overexpressed in cisplatin (DDP)-resistant human lung adenocarcinoma cells (A549/DDP cells) compared with A549 cells. The expression of KIF4A in A549 or A549/DDP cells significantly affects cisplatin resistance but the detailed mechanisms remain unclear. Here, we performed co-immunoprecipitation experiments to show that the tail domain of KIF4A interacted with the N-terminal of LRP. Immunofluorescence images showed that both the ability of binding to LRP and the motility of KIF4A were essential for the dispersed cytoplasm distribution of LRP. Altogether, our results shed light on a potential mechanism in that motor protein KIF4A promotes drug resistance of lung adenocarcinoma cells through transporting LRP-based vaults along microtubules towards the cell membrane. Thus KIF4A might be a cisplatin resistance-associated protein and serves as a potential target for chemotherapeutic drug resistance in lung cancer.
Introduction
Chemotherapy is one of the most effective strategies of cancer treatment. However, multidrug resistance (MDR) where cancer cells become resistant to different cytotoxic drugs is the major impediment to effective cancer chemotherapy (Kathawala et al., 2015) . There are many factors involved in this process, including overexpression of transportassociated proteins in tumor cells, such as Pglycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), breast cancer resistance protein (BCRP), and lung resistance-related protein (LRP), all of which have been considered as major factors in (Scheper et al., 1993; Germann, 1996; Gottesman et al., 2002) .
LRP, also known as the major vault protein (MVP), is the main structural component of vault complexes which are the largest intracellular ribonucleoprotein particles (Scheffer et al., 1995) . LRP was found to be overexpressed in doxorubicin resistant non-small cell lung cancer cells which had no P-gp expression (Scheper et al., 1993) . High expression of LRP was observed in many tumor cells resistant to various cytotoxic drugs including mitoxantrone, doxorubicin, methotrexate, vincristine, etoposide, cisplatin, and cytarabine (Mossink et al., 2003) , suggesting that LRP played an important role in drug resistance. However, the detailed molecular mechanisms whereby LRP participates in drug resistance are still unclear. It was reported that LRP-based vaults were involved in nucleus/cytoplasm transport, and that this may decrease the nucleus/cytoplasm distribution ratio of drugs (Scheffer et al., 1995) . However, the majority of LRP-based vaults are localized in cytoplasm and no more than 5% of LRP-based vaults were associated with the nucleus (Chung et al., 2005) . In addition, some LRP-based vaults were observed moving rapidly along microtubules in cytoplasm (Slesina et al., 2006; van Zon et al., 2006; Yang et al., 2010) . These observations suggest that LRP-based vaults might be involved in intracellular transport in addition to nucleus/ cytoplasm transport and function as a drug delivery vehicle which moves cytotoxic drugs away from their subcellular targets out of cells so as to contribute to the drug-resistance process in tumor cells. However, it is unknown if there are any motor proteins transporting LRP-based vaults to move along microtubules towards cell membrane inside of cells.
Motor protein KIF4A, a member of the Kinesin-4 family, is a microtubule-based plus-end directed motor protein. KIF4A has been reported to participate in a variety of cell processes, including intracellular trafficking of HIV gag and integrin-β 1 (Martinez et al., 2008; Willemsen et al., 2014) , mitotic progression (Zhu and Jiang, 2005; Wandke et al., 2012) , DNA damage response (Wu et al., 2008) and brain neuron development (Midorikawa et al., 2006) . It has been also reported that KIF4A was upregulated in lung cancer and could serve as a prognostic biomarker and therapeutic target for lung cancer (Taniwaki et al., 2007; Zhu et al., 2015) . Our previous studies showed that KIF4A is also involved in cisplatin resistance in lung cancer cells (Xiao et al., 2016) . However, the detailed mechanisms are still not clear.
In this study, to investigate whether the LRP and KIF4A are involved in the multidrug resistance of lung cancer cells, the expression of LRP and KIF4A was examined in cisplatin-resistant A549/DDP cells and A549 cells. The underlying mechanism was then investigated by examining how KIF4A regulated the intracellular distribution of LRP. These findings reveal the potential role of Kinesin KIF4A in regulating drug resistance in lung cancer cells by transporting LRP-based vaults-drug delivery vehicles.
Materials and methods

Cell culture and transfection
Human lung adenocarcinoma A549 cells and cisplatin (DDP)-resistant A549/DDP cells were cultured in RPMI 1640 medium containing 10% (0.1 mg/ml) fetal calf serum (Invitrogen, Carlsbad, CA, USA) at 37 °C and 5% CO 2 . DDP (2 µg/ml; Sigma-Aldrich, St. Louis, USA) was added to the culture medium of A549/DDP cells. The cells were transfected with 50 nmol/L small interfering RNAs (siRNAs) and/or 0.2-1.0 µg of plasmids using the TurboFect transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA). Cells were harvested or fixed for immunoprecipitation, immunoblotting, or immunofluorescence analysis 36-48 h after transfection.
Plasmids, siRNA, and antibodies
A full-length human LRP complementary DNA (cDNA; GenBank: X79882.2) was generated by polymerase chain reaction (PCR) and subcloned into EcoR1/BamHI sites of the mammalian expression vector pEGFP-C1 or pFlag-C1 using the primers 5'-CCG GAA TTC ATG GCA ACT GAA GAG TTC ATC-3' and 5'-CGC GGA TCC GCG CAG TAC AGG CAC CAC GT-3'. KIF4A expression plasmids were generated as described previously (Zhu and Jiang, 2005) . Fragments of KIF4A and LRP were subcloned into vectors of pEGFP-C1 or pFlag-C1, respectively. All plasmids were confirmed by DNA sequencing (GeneWiz, Suzhou, China). siRNA specifically targeting 3'-UTR of KIF4A (5'-GGA ATGAGGTTGTGATCTT-3') was synthesized by GenePharma (Shanghai, China). Polyclonal rabbit anti-KIF4A antibodies were generated as previously described (Zhu and Jiang, 2005) . Rat anti-α-tubulin, rabbit anti-green fluorescent protein (GFP), and mouse anti-Flag antibodies were purchased from SigmaAldrich. Mouse anti-LRP was purchased from BD Biosciences (San Jose, CA, USA). All secondary antibodies were obtained from Life Technologies Inc. (Grand Island, NY, USA).
Immunoprecipitation and Western blot
A549 cells were cultured in 60-mm plates and transfected with 3 µg of plasmids. Two days after transfection, the cells were lysed by NP-40 buffer (50 mmol/L Tris-Cl, 150 mmol/L NaCl, 1% (0.01 g/ml) NP-40, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 1 mmol/L dithiothreitol (DTT), 10 U/ml aprotinin, 20 µg/ml leupeptin, 50 µmol/L Na 3 VO 4 , 5 mmol/L β-glycerophosphate, 5 mmol/L NaF, 10% (v/v) glycerol). Lysates were mixed with anti-KIF4A antibodies at 4 °C overnight and then incubated either with protein A (CST, USA) beads at 4 °C for 2 h or with anti-Flag M2 magnetic beads (Sigma-Aldrich) at 4 °C for 3 h. Immunoprecipitates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a polyvinylidene fluoride (PVDF) membrane, and then immunoblotted with various primary antibodies and secondary antibodies.
Immunofluorescence analyses
A549 or A549/DDP cells (3×10 4 ) were grown on glass coverslips in a 24-well plate and cultured at 37 °C in a 5% CO 2 incubator overnight. Then cells were transfected with 50 nmol/L KIF4A siRNA and/or 1 μg of plasmids. Thirty-six hours after transfection, cells were fixed in phosphate-buffered saline (PBS) containing 3% (0.03 g/ml) formaldehyde and 2% (0.02 g/ml) sucrose for 15 min followed by incubation in PBS containing 0.1 mol/L glycine for 5 min. Cells are penetrated and blocked with PBS containing 10% (0.1 g/ml) goat serum and 0.4% (4 g/L) TritonX-100 for 30 min. After washing with PBS-TX (PBS containing 0.1% (v/v) TritonX-100) three times, cells were incubated with primary antibody in PBS-TX for 2-3 h at room temperature followed by secondary antibody in PBS-TX for 1-2 h.
Finally, cells were stained with 1 µg/ml of 4'6-diamidino-2-phenylindole (DAPI) in PBS-TX for 3 min and the coverslips were mounted in 4 µl of FluroGuard Antifade solution (Bio-Rad Inc., San Diego, California, USA) and sealed with Cytoseal-60 (Fisher Inc., Rockford, IL, USA).
Results
Kinesin KIF4A interacted with LRP on the microtubules in the cytoplasm
It was reported that LRP was involved in MDR by mediating drug transport processes inside cells (Steiner et al., 2006) . However, the regulation of intracellular distribution of LRP has remained unclear. Given the fact that LRP-based vaults can move along microtubules (van Zon et al., 2006) , we explored the potential binding partners of LRP among microtubule-based motor proteins, the Kinesin superfamily (Kifs), in A549/DDP cells. Previously, we found that Kinesin KIF4A was highly expressed in lung cisplatin-resistant A549/DDP cells and KIF4A participated in regulating cisplatin resistance of A549/DDP cells (Xiao et al., 2016) . We then investigated the relationship between LRP and KIF4A.
First, we examined the expression of LRP and KIF4A in A549 and A549/DDP cells. Consistent with previous reports, LRP and KIF4A were highly expressed in A549/DDP cells and much more than in A549 cells in both mRNA and protein levels (Trussardi et al., 1998; Xiao et al., 2016; Zhang et al., 2016) , as shown in Fig. S1 . Then we ectopically expressed Flag-tagged LRP in A549/DDP cells and performed co-immunoprecipitation assay using antiFlag antibodies followed by immunoblotting with anti-KIF4A antibody. Western blot results showed that KIF4A could co-immunoprecipitate with Flag-LRP (Fig. 1a) . To confirm the interaction of KIF4A and LRP, we performed immunoprecipitation experiments using A549/DDP cell lysates with anti-LRP antibodies, which were then immunoblotted with anti-KIF4A antibodies. As shown in Fig. 1b , KIF4A could be immunoprecipitated with LRP by anti-LRP antibodies. These results indicated an interaction between KIF4A and LRP in A549/DDP cells.
It is well-known that KIF4A is a microtubuleassociated motor protein. We used immunofluorescence analyses to examine the intracellular localization of LRP and KIF4A. As shown in Fig. 1c, KIF4A was partially co-localized with LRP on microtubules in the cytoplasm. Taken together, these results indicated that LRP interacted with motor protein KIF4A and was co-localized on microtubules with KIF4A in the cytoplasm.
Tail domain of KIF4A interacted with Nterminal of LRP
To further investigate which domain of KIF4A was necessary for its interaction with LRP, we constructed several plasmids expressing GFP-tagged truncated KIF4A. As shown in Fig. 2a , Kinesin KIF4A harbors multiple well-characterized functional domains. We respectively co-expressed Flag-LRP and GFP-KIF4A FL (full-length) or truncated version N351 (motor domain), N1018 (motor and coiled-coil/Stalk domain), C896 (coiled-coil/Stalk and tail domain) or C230 (tail domain) in A549 cells. Co-immunoprecipitation experiments showed that both KIF4A-C230 and KIF4A-C896 bound LRP similarly to KIF4A-FL. In contrast, the N-terminal of KIF4A (N351 and N1018) cannot bind LRP (Fig. 2b) .
Previous studies have shown that LRP contains EF-hands (aa 131-143) interacting with calcium and a coiled-coil domain (aa 648-800) for intermolecular interaction . We next constructed plasmids expressing Flag-tagged LRP-WT (full-length), N447 (N-terminal, aa 1-447) or C446 (C-terminal, aa 448-893) (Fig. 2c) . Then we co-transfected these plasmids with pEGFP-KIF4A for immunoprecipitation assays. As shown in Fig. 2d , GFP-KIF4A was immunoprecipitated by LRP-WT and LRP-N447, while the LRP-C446 failed to bind GFP-KIF4A. These results suggested that the N-terminal of LRP was necessary for its interaction with KIF4A. Altogether, the results indicated that the tail domain of KIF4A could interact with the N-terminal of LRP.
KIF4A controlled intracellular trafficking of LRP
The N-terminal of LRP interacted with the motor domain of Kinesin KIF4A. Our previous studies had shown that Kinesin KIF4A played a part in cisplatin resistance of lung cancer cells (Xiao et al., 2016) . We therefore proposed that motor protein KIF4A might be involved in regulation of the cytoplasm trafficking of LRP. To examine whether cytoplasmic distribution of LRP could be regulated by Kinesin KIF4A, siRNAs were used to knock down the endogenous KIF4A in A549/DDP cells. As shown in Fig. 3a, KIF4A was depleted by around 90% by transfection of siRNA specific targeted 3'-UTR of KIF4A in A549/DDP cells. Immunostainning experiments showed that LRP was dispersed throughout the cytoplasm in control siRNA transfected cells, while a great deal of LRP clustered in the perinuclear region in KIF4A-depleted cells (Fig. 3b) . To display the intracellular distribution of LRP more clearly, we quantified 4-5 areas at random at the perinuclear region or the cytoplasm for optical intensity analysis in every cell (Fig. 3c) and calculated the intensity ratio of LRP localization at the perinuclear versus cytoplasm. As shown in Fig. 3d , more LRP clustered in the perinuclear region in KIF4A-depleted cells. These results suggest that dispersed cytoplasmic distribution of LRP depended on the motor protein KIF4A.
To examine the requirement of KIF4A in dispersed cytoplasmic distribution of LRP in A549/DDP cells, we performed RNA interference (RNAi) rescue experiments to transfect siRNA specifically targeting 3'-UTR of KIF4A and simultaneously expressing different KIF4A truncated mutants in A549/DDP cells. As shown in Fig. 4a , endogenous KIF4A was depleted efficiently while exogenous proteins of GFP-KIF4A-FL, GFP-KIF4A-N351, GFP-KIF4A-N1018, GFP-KIF4A-C896, or GFP-KIF4A-C230 were ectopically expressed in A549/DDP cells. We performed immunostaining experiments to investigate the cytoplasmic distribution of LRP in detail in these A549/DDP cells. Cells expressing GFP-KIFA-FL but lacking endogenous KIF4A displayed a normal cytoplasmic distribution of LRP. In contrast, LRP clustered in the perinuclear region in cells with depleted KIF4A but expressing truncated KIF4A mutants N351, N1018, C896, or C230 (Figs. 4b and 4c) .
Taken together, all the results indicated that Kinesin KIF4A was involved in the cytoplasmic trafficking of LRP. As cargo, LRP interacted with the tail domain of KIF4A and then was transported along the microtubules towards cell membrane. 
Discussion
KIF4A, a plus-ends directed microtubule-based motor protein, is essential for chromosome condensation, congression, and spindle microtubule dynamics during mitosis. Here, we report that Kinesin KIF4A promoted a drug-resistance process in lung cancer by binding and transporting LRP throughout the cytoplasm. We also determined that the tail domain (cargo-binding domain) of KIF4A interacted with the N-terminal of LRP (Fig. 2) . Cytoplasmic distribution of LRP required full-length of KIF4A, suggesting that LRP-based vaults might be one of cytoplasmic cargos of motor protein KIF4A.
LRP has been identified as one of the MDR proteins given the fact that there is a significant association between LRP expression in tumor tissues and the clinical effect of chemotherapy in the survival rates of many types of cancer patients (Scheffer et al., 2000) . However there are still debates on whether LRP is involved in drug resistance directly. Mossink et al. (2002) reported that knockdown of LRP did not induce hypersensitivity to cytotoxic agents. However, other studies suggested that LRP is involved in drug resistance in human breast cancer MCF-7/ADR cells by directly transporting doxorubicin from the action target (nucleus) to cytoplasm (Han et al., 2012) . At the same time, as the MVP, LRP is the main structural component of vault complex. The other two vault proteins are vault poly (ADP-ribose) polymerase (VPARP) and telomeraseassociated protein 1 (TEP1) (Mossink et al., 2003) . It was reported that LRP self-associated by its coiled-coil domain (CC domain, aa 648-800), and interacted with VPARP by its N-terminal domain . Since the ratio of VPARP to MVP molecules is 8/96 in the vaults, VPARP will not occupy all the N-terminal of LRP. Lots of EF-hand domains (aa 131-143) at the N-terminal may be exposed for interacting with other proteins (Yu et al., 2002) . The results in Fig. 2 indicated that the truncated mutant without the N-terminal of LRP (LRP-C446) cannot bind KIF4A, suggesting that the N-terminal of LRP was essential for interacting with KIF4A. Further studies are needed to determine if the EF-hand motif and the Ca 2+ binding are essential for LRP-binding KIF4A.
Most vaults appeared very mobile throughout the cytoplasm as assessed by timelapse imaging with photoactivatable PA-GFP labeled LRP (Yang et al., 2010) . Though there are studies supporting the idea that LRP functioned on nucleocytoplasmic trafficking and transport, no more than 5% of vault particles were associated with the nucleus (Kickhoefer et al., 2002; Chung et al., 2005) , suggesting that LRP might be involved in intracellular transport. Our results indicated that many LRP clustered in the perinuclear region after depletion of KIF4A (Fig. 3) . This phenotype could be recovered by the expression of the full-length KIF4A, but not the motor domain or tail domain truncated mutants of KIF4A (Fig. 4) . It is well-known that Kinesin motors are involved in the major microtubule-dependent intracellular transport pathways. Both the motor domain and the tail domain are necessary for this process. The Kinesin motor domain could utilize ATP to fuel their movement along microtubules and the tail domain is essential for cargo binding. In KIF4A-depleted cells expressing KIF4A-N351 or KIF4A-N1018, LRP cannot interact with KIF4A-N351 and KIF4A-N1018 so that LRP could not be transported by these KIF4A mutants. This results in perinuclear localization of LRP in these cells. However, in KIF4A-depleted cells expressing KIF4A-C896 or KIF4A-C230, LRP also clustered in the perinuclear region since these mutants cannot move along microtubules without the motor domain. These results suggest that the tail domain of KIF4A is needed for LRP binding, and the motor domain of KIF4A is essential for LRP intracellular trafficking.
Taken together, our results indicate that motor protein KIF4A can bind and transport LRP, the major component of vault complex, in cisplatin-resistant lung cancer cells. Given the fact that LRP-based vaults play an essential role in driving cytotoxic drugs away from their subcellular targets, our studies reveal a potential mechanism by which Kinesin KIF4A contributes to the drug-resistance process in lung cancer cells by transporting LRP-based vaults. In addition, Kinesin KIF4A might also serve as a novel therapeutic target in drug-resistant lung cancer.
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